Jorge Zeron-Medina
Overview
Explore the profile of Jorge Zeron-Medina including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
776
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hamilton E, Wang J, Oza A, Patel M, Ulahannan S, Bauer T, et al.
Mol Cancer Ther
. 2023 Jul;
22(10):1154-1165.
PMID: 37486983
AZD5153, a reversible, bivalent inhibitor of the bromodomain and extraterminal family protein BRD4, has preclinical activity in multiple tumors. This first-in-human, phase I study investigated AZD5153 alone or with olaparib...
2.
Zhang P, Kitchen-Smith I, Xiong L, Stracquadanio G, Brown K, Richter P, et al.
Cancer Res
. 2021 Feb;
81(7):1667-1680.
PMID: 33558336
Insights into oncogenesis derived from cancer susceptibility loci (SNP) hold the potential to facilitate better cancer management and treatment through precision oncology. However, therapeutic insights have thus far been limited...
3.
Cedres S, Felip E, Cruz C, Martinez de Castro A, Pardo N, Navarro A, et al.
J Natl Cancer Inst
. 2018 Mar;
110(8):914-917.
PMID: 29529211
Heat shock proteins (HSPs) are molecular chaperones that maintain proteins in their correct conformation to ensure stability and protect carcinoma cells from apoptosis. HSP90 inhibitors (HSP90i) block multiple targets simultaneously,...
4.
Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D, et al.
JAMA Oncol
. 2018 Jan;
4(3):351-357.
PMID: 29327044
Importance: Derived neutrophils/(leukocytes minus neutrophils) ratio (dNLR) and lactate dehydrogenase (LDH) level have been correlated with immune checkpoint inhibitor (ICI) outcomes in patients with melanoma. Objective: To determine whether pretreatment...
5.
Salcedo Allende M, Zeron-Medina J, Hernandez J, Macarulla T, Balsells J, Merino X, et al.
Pancreas
. 2017 Jul;
46(7):913-920.
PMID: 28697132
Objectives: Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer. Overexpression of Yes associated protein 1 (YAP1), a downstream target of Hippo pathway, implicated in regulation of cell growth and apoptosis,...
6.
Stracquadanio G, Wang X, Wallace M, Grawenda A, Zhang P, Hewitt J, et al.
Nat Rev Cancer
. 2016 Mar;
16(4):251-65.
PMID: 27009395
Decades of research have shown that mutations in the p53 stress response pathway affect the incidence of diverse cancers more than mutations in other pathways. However, most evidence is limited...
7.
Zeron-Medina J, Ochoa de Olza M, Brana I, Rodon J
Semin Oncol
. 2015 Nov;
42(6):775-87.
PMID: 26615125
Advances in tumor biology and human genetics that have identified driver events and critical dependencies, together with the development of drugs for specific targets, hold promise for an era of...
8.
Lewis A, Freeman-Mills L, de la Calle-Mustienes E, Giraldez-Perez R, Davis H, Jaeger E, et al.
Cell Rep
. 2014 Aug;
8(4):983-90.
PMID: 25131200
A rare germline duplication upstream of the bone morphogenetic protein antagonist GREM1 causes a Mendelian-dominant predisposition to colorectal cancer (CRC). The underlying disease mechanism is strong, ectopic GREM1 overexpression in...
9.
Zeron-Medina J, Wang X, Repapi E, Campbell M, Su D, Castro-Giner F, et al.
Cell
. 2013 Oct;
155(2):410-22.
PMID: 24120139
The ability of p53 to regulate transcription is crucial for tumor suppression and implies that inherited polymorphisms in functional p53-binding sites could influence cancer. Here, we identify a polymorphic p53...
10.
Zeron-Medina J, Rodriguez-Covarrubias F, Garcia-Mora A, Guerrero-Hernandez M, Chable-Montero F, Albores-Saavedra J, et al.
Am Surg
. 2011 Mar;
77(1):112-3.
PMID: 21396319
No abstract available.